Edition:
India

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

17.00USD
15 Dec 2017
Change (% chg)

$0.25 (+1.49%)
Prev Close
$16.75
Open
$16.80
Day's High
$17.15
Day's Low
$16.60
Volume
670,775
Avg. Vol
180,394
52-wk High
$17.70
52-wk Low
$9.30

Chart for

About

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $489.96
Shares Outstanding(Mil.): 46.55
Dividend: --
Yield (%): --

Financials

BRIEF-ING Groep NV Reports 6.70 Pct Passive Stake In Sucampo Pharmaceuticals As Of Dec 7 - SEC Filing

* REPORTS A 6.70 PCT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DEC 7 - SEC FILING Source text: (http://bit.ly/2yseEW4) Further company coverage:

14 Dec 2017

BRIEF-Linden Capital Reports A 5.1 Pct Passive Stake In Sucampo Pharmaceuticals

* LINDEN CAPITAL L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DECEMBER 6, 2017 - SEC FILING Source text : [http://bit.ly/2jz2syj] Further company coverage:

08 Dec 2017

Sucampo weighs sale after fielding takeover interest: Bloomberg

Sucampo Pharmaceuticals Inc is considering selling itself after receiving takeover interest, Bloomberg reported on Thursday, citing people familiar with the matter.

08 Dec 2017

BRIEF-Sucampo reports Q3 GAAP earnings per share $0.19

* Q3 earnings per share view $0.25 -- Thomson Reuters I/B/E/S

01 Nov 2017

BRIEF-Sucampo Pharmaceuticals announces FDA acceptance of sNDA for AMITIZA

* Sucampo Pharmaceuticals announces FDA acceptance of sNDA for amitiza in children with pediatric functional constipation, with priority review designation

29 Sep 2017

BRIEF-Cancer Prevention Pharmaceuticals receives $9.5 mln in additional funding from Sucampo

* Cancer Prevention Pharmaceuticals receives $9.5 million in additional funding from sucampo following phase 3 trial progress

11 Sep 2017

BRIEF-Sucampo Pharmaceuticals and Four Irvington Centre Associates enters into second amendment

* Sucampo Pharmaceuticals - On Sept 5, 2017, Co and Four Irvington Centre Associates, LLC entered into a second amendment to lease agreement- SEC filing

09 Sep 2017

BRIEF-Sucampo reports Q2 GAAP loss per share $3.92

* Q2 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

02 Aug 2017

BRIEF-Sucampo Pharmaceuticals says board voted to increase authorized size of board from six to seven

* Sucampo Pharmaceuticals Inc - On July 15 co's board voted to increase authorized size of board by one, from six to seven Source text: [http://bit.ly/2tgJFdK] Further company coverage:

20 Jul 2017

Earnings vs. Estimates